Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether the use of different dose of LMWH compared with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| lung lmwh1 | Active Comparator | use LMWH once daily after lung resection |
|
| lung lmwh2 | Experimental | use LMWH twice daily after lung resection |
|
| lung Fondaparinux | Experimental | use Fondaparinux once daily after lung resection |
|
| eso lmwh1 | Active Comparator | use LMWH once daily after esophagectomy |
|
| eso lmwh2 | Experimental | use LMWH twice daily after esophagectomy |
|
| eso Fondaparinux | Experimental | use Fondaparinux once daily after esophagectomy |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fondaparinux | Drug | 2.5mg IH qd(8AM) after operation |
|
| Measure | Description | Time Frame |
|---|---|---|
| TEG values | 1.5ml aterial blood sample will be obtained daily for TEG , and the vulues of TEG,such as R,K,Alpha angle,MA,G,CI ,will be measured | three days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| bleeding quantity of chest drainage | all drain from chest tube are gathered and hematocrits are measured to calculate the quantities of bleeding | three days after surgery |
| incidence rate of deep venous thromboembolism（DVT) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lizhen Xuan | Shanghai Zhongshan Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongshan Hospital | Shanghai | 200032 | China |
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D004938 | Esophageal Neoplasms |
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077425 | Fondaparinux |
| D017762 | Nadroparin |
| ID | Term |
|---|---|
| D009844 | Oligosaccharides |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D006495 | Heparin, Low-Molecular-Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nadroparin Calcium | Drug | 4100AxaIU IH qd(8AM) after operation |
|
|
| Nadroparin Calcium | Drug | 4100AxaIU IH q12h(8Am,8Pm) after operation |
|
|
incidence of DVT is measured by vascular ultrasonography
| after surgery up to 7 days |
| inhospital mortality | the number of death in the period of hospital stay | after surgery up to 28 days |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D006258 | Head and Neck Neoplasms |
| D004066 | Digestive System Diseases |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006493 |
| Heparin |
| D006025 | Glycosaminoglycans |